Drug intelligence / Profile preview

SAL0104

Development stage: Unknown
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SAL0104 is an oral small molecule inhibitor of factor XIa, developed by Shenzhen Salubris Pharmaceuticals for the treatment of thrombosis and other cardiovascular diseases. As a novel antithrombotic agent, it targets factor XIa in the coagulation cascade to reduce thrombus formation while potentially minimizing bleeding risk compared to conventional anticoagulants. The drug is currently in Phase I clinical trials, with studies evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects[1][2][3].

Other names: SAL 0104SAL0104SAL-0104

Targets

Factor XIa

Beyond the preview

Go deeper on SAL0104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL0104.

Explore the full profile